Skip To Main Content
Barbara Stokes on Muck Rack

Barbara Stokes

As seen in: Nature, Cell Chemical Biology, Cell Press, American Society for Microbiology (ASM)
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work. Claim your profile

Get in touch with Barbara

Contact Barbara, search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Is this you?

As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile

Articles

Mitigating the risk of antimalarial resistance via covalent dual-subunit inhibition of the Plasmodium proteasome

|
By Ioanna Deni, Antimicrobial resistance, Barbara Stokes, Kurt E. Ward
| Cell Chemical Biology Verified
Synthesis of tert-butyl N-[(5S)-5-[[(2R)-1-acetylpyrrolidine-2-carbonyl]amino]-6-oxo-6-[[(1R)-2-phenyl-1-[(1S,2S,6R,8S)-2,9,9-trimethyl-3,5-dioxa-4-boratricyclo[6.1.1.02,6]-decan-4-yl]-ethyl]amino]hexyl]carbamate (MMV1579506) To a solution of (1R)-2-phenyl-1-[(1S,2S,6R,8S)-2,9,9-trimethyl-3,5-dioxa-4-boratricyclo-[6.1.1.02,6]decan-4-yl]ethanamine.trifluoroacetic acid salt (1.0 g, 2.41 mmol) in dimethyl formamide (15 mL) was added...
Open in Who Shared Issue with article?

A G358S mutation in the Plasmodium falciparum Na+ pump PfATP4 confers clinically-relevant resistance to cipargamin - Nature Communications

|
By Deyun Qiu, John Tanner, Jocelyn Sietsma Penington, Guoyue Xu, Abhai Tripathi, Tomas Yeo, Barbara Stokes, Melanie C. Ridgway, Anthony T. Papenfuss, Ben Corry, Photini Sinnis, David A Fidock
| Nature Verified
Abstract Diverse compounds target the Plasmodium falciparum Na+ pump PfATP4, with cipargamin and (+)-SJ733 the most clinically-advanced. In a recent clinical trial for cipargamin, recrudescent parasites emerged, with most having a G358S mutation in PfATP4. Here, we show that PfATP4G358S parasites can withstand micromolar concentrations of cipargamin and (+)-SJ733, while remaining susceptible to antimalarials that do not target PfATP4.
Open in Who Shared Issue with article?

Plasmodium berghei K13 Mutations Mediate In Vivo Artemisinin Resistance That Is Reversed by Proteasome Inhibition

|
By Nelson V. Simwela, Barbara Stokes, Dana Aghabi, Matt Bogyo
| American Society for Microbiology (ASM)
Editor's Pick Research Article | Host-Microbe Biology Nelson V. Simwela, Barbara H. Stokes, Dana Aghabi, Matt Bogyo, David A. Fidock, Andrew P. Waters Louis H. Miller, Editor DOI: 10.1128/mBio.02312-20 ABSTRACT The recent emergence of Plasmodium falciparum parasite resistance to the first line antimalarial drug artemisinin is of particular concern. Artemisinin resistance is primarily driven by mutations in the P.
Open in Who Shared Issue with article?
See all 8 articles